Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT06741228

ClinicalTrials.gov

Trial ID
T-ctgov-NCT06741228
Registry
ClinicalTrials.gov
NCT number
NCT06741228
Asset
DT120 (registry title MM120)
Sponsor, as registered
Definium Therapeutics US, Inc.
Phase
PHASE3
Indication
Generalized Anxiety Disorder
Status
ACTIVE_NOT_RECRUITING
Start date
2024-12-11
Primary completion
2026-07-15
Registered countries
United States
Sites
34

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-15

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site. Supersedes the row verified 2026-08-31. Record last updated 2026-09-02: primary_completion_date refined from 2026-07 to 2026-07-15; overall_status ACTIVE_NOT_RECRUITING unchanged.

Company

Through DT120 (registry title MM120): Definium Therapeutics

Cited in

Issues quoting NCT06741228 in their own text.